CTI BioPharma Corp. (CTIC) is priced at $3.43 after the most recent trading session. At the very opening of the session, the stock price was $3.22 and reached a high price of $3.35, prior to closing the session it reached the value of $3.34. The stock touched a low price of $3.20.
Recently in News on October 13, 2020, CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia. – Completion of Submission Expected in First Quarter 2021 -. You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
CTI BioPharma Corp. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.68 on 10/06/20, with the lowest value was $0.62 for the same time period, recorded on 03/16/20.
CTI BioPharma Corp. (CTIC) full year performance was 328.21%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CTI BioPharma Corp. shares are logging -6.79% during the 52-week period from high price, and 453.23% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.62 and $3.68.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1443316 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CTI BioPharma Corp. (CTIC) recorded performance in the market was 111.39%, having the revenues showcasing 94.19% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 239.18M, as it employees total of 25 workers.
CTI BioPharma Corp. (CTIC) in the eye of market guru’s
During the last month, 0 analysts gave the CTI BioPharma Corp. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.57, with a change in the price was noted +2.36. In a similar fashion, CTI BioPharma Corp. posted a movement of +215.00% for the period of last 100 days, recording 2,538,013 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CTIC is recording 0.12 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.04.
CTI BioPharma Corp. (CTIC): Stocks Technical analysis and Trends
Raw Stochastic average of CTI BioPharma Corp. in the period of last 50 days is set at 92.09%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 91.92%. In the last 20 days, the company’s Stochastic %K was 88.10% and its Stochastic %D was recorded 86.08%.
If we look into the earlier routines of CTI BioPharma Corp., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 111.39%. Additionally, trading for the stock in the period of the last six months notably improved by 278.68%, alongside a boost of 328.21% for the period of the last 12 months. The shares increased approximately by 8.44% in the 7-day charts and went down by 218.10% in the period of the last 30 days. Common stock shares were driven by 94.19% during last recorded quarter.